Related Experiment Video
Updated: Aug 13, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Diltiazem-associated thrombocytopenia
1Department of Pharmacy, Mission-St. Joseph's Health System, Asheville, North Carolina 28801, USA.
Abstract:
Nine days after starting diltiazem therapy for new-onset atrial fibrillation, a patient's platelet count had diminished to 61 x 10(3)/mm3, and 2 weeks later the nadir was reached at 23 x 10(3)/mm3. No hypersensitivity reaction otherwise was noted, and other hematologic values were unaffected. The patient's platelet counts were not affected by platelet transfusions. Bone marrow examination showed normal to increased numbers of megakaryocytes, suggesting peripheral destruction. After discontinuing diltiazem and administering high-dose immunoglobulin infusions, the platelet count returned to normal. This case suggests an immune-mediated cause for thrombocytopenia after exposure to diltiazem.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Therapeutic Drug Monitoring: Affecting Factors
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Cardiomyopathy II: Dilated Cardiomyopathy
Transient Ischemic Attack l: Introduction

